港股異動 | 希瑪眼科(3309.HK)漲7% 斥3.85億元成深圳愛康健控股股東
格隆匯9月3日丨希瑪眼科(3309.HK)午後快速拉昇漲7%,現報8.34港元,暫成交7486萬港元,總市值96億港元。公司午間公吿,斥3.85億元人民幣收購深圳愛康健55%股權成公司控股股東,拓展眼+牙連鎖醫療服務。董事相信在同一處所或相鄰範圍內提供兩種醫療服務,將締造豐碩協同效益,此舉將提升集團在中國作為優質專業醫療服務供應商的品牌及影響力。此外,日前中期業績顯示,上半年股東應占溢利1371.2萬港元,同比實現扭虧為盈。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.